Stock Outlook:
Aurobindo Pharma (AUROPHARMA) exhibited robust intraday buying on December 18, 2025, opening at ₹1190, hitting high ₹1213.70 (+2%), low ₹1176.60 (-1.15%), and closing at ₹1209.30 (+1.37%) with 947k volume (1.4x 20D avg) and 52% delivery, signaling strong hands interest amid pharma rebound. Detailed technicals reveal strong buy oscillators overriding bearish MAs, supported by Q2 FY26 revenue growth to ₹8286 Cr despite FDA procedural observations. Fundamentals underscore value at P/E 20.52 (sector low), low debt, and injectables expansion potential.
Detailed Technical Analysis:
Oscillators (Strong Buy): RSI(14) 49 neutral-bullish, STOCH(9,6) 72 buy, STOCHRSI(14) 100 overbought-buy, Williams %R -44 buy, CCI(14) 128 buy; MACD(12,26) -2.9 sell but histogram narrowing. ADX(14) 24 neutral, ATR(14) 9.46 high volatility favors breakouts.
Moving Averages (Bearish, but turning): 3 buy/9 sell—MA5 ₹1120 sell, MA10 ₹1145 sell, MA20 ₹1172 sell, MA50 ₹1130 sell, MA100 ₹1165 sell, MA200 ₹1139 sell. Price above short-term EMAs signals intraday strength; golden cross potential if MA20 crosses MA50.
Pivot & Intraday Action: Classic pivots: R3 ₹1227, R2 ₹1217, R1 ₹1211, Pivot ₹1202, S1 ₹1192, S2 ₹1182, S3 ₹1172. Stock broke R1 ₹1206 on volume, closed near R2 with doji-like candle hinting continuation; VWAP ₹1202 hold key for bulls.
Chart Patterns & Outlook: Rounding bottom from ₹1130 lows, Fibonacci 61.8% retrace at ₹1180 support. Bullish divergence on RSI vs price; target ₹1230 (R3) short-term, ₹1356 52W high long-term if breaks MA50 with volume >1M.
Detailed Fundamental Analysis:
Q2 FY26 Results (Nov 2025): Revenue ₹8286 Cr (+6% YoY, +5% QoQ), EBITDA ₹1687 Cr (margin 20.37% vs 21.38% prior, -101 bps), PAT ₹848 Cr (+3% YoY). H1 FY26: Sales ₹16,154 Cr, profit ₹1673 Cr. US generics 47% revenue (stable), Europe +12%, ARV +15%.
Valuations & Ratios: Market cap ₹70,236 Cr, P/E 20.52 (sector 39.68), forward P/E 17.5, P/B 2.16 (sector 4.2), EV/EBITDA 11.2. ROE 10.67% (sector 12%), ROCE 13.2%, debt/equity 0.24 low, current ratio 1.8. Dividend yield 0.49%, EPS TTM ₹58.93 (-4% YoY).
Growth Drivers: Injectables capex reset to ₹1500 Cr FY26 (up from ₹1000 Cr), Merck CDMO roadmap, Kakinada SEZ port infra for exports. Promoter holding 51.74% steady, FII 19.2% up QoQ.
Auropharma Positive & Negative Points:
Price/Volume: +1.37% gain with 52% delivery and 1.4x volume breakout above R1; countered by YTD -3.2% lag, trading below 52W high ₹1356 near MA20.
Technicals: 6/8 oscillators signal buy with pivot ₹1202 hold; offset by 9/12 MAs sell and negative MACD.
Financials: Low P/E 20.5, +6% revenue, minimal debt shine; EBITDA margin dipped -101 bps with EPS -4% YoY.
Operations: Injectables/CDMO growth and Europe +12% boost prospects; US FDA Form 483 (5 procedural obs) adds caution.
Buying Reason, News & Impact:
Today’s Surge: Pharma index +0.8% rebound, high delivery amid Q2 momentum carryover (PAT beat estimates), short-covering post-FDA dip. No specific Dec 18 trigger; sector rotation from IT to pharma on global cues.
Key News/Event: US FDA inspected APL Healthcare Unit-IV (Dec 8-17, 2025): 5 procedural observations (no data integrity issues)—company filing response by Jan 2026; historical procedural fixes resolved quickly, minimal impact (stock -2% post-news, recovered). Positive: Injectables bet, FY26 guidance 12-14% revenue growth. Impact: Neutral-short term (regulatory overhang caps), bullish medium-term on diversification.
Short & Long-Term Levels:
Short-Term (1-4 weeks): Buy ₹1180-1192 (S1-S2, Fib 61.8%), target ₹1211-1227 (R1-R3), stop ₹1172. Hold above ₹1202 pivot.
Long-Term (6-12 months): Support ₹1130-1160 (MA50/200 cluster), target ₹1300-1430 (Analyst avg, 20% upside). Bullish above ₹1248 breakout.
Disclaimer & Disclosure:
Educational content only; not investment advice or recommendation. No positions held; data from public sources as of Dec 18, 2025, 11 PM IST. Markets volatile—consult SEBI-registered advisor.
Past performance no future guarantee.